PAR2025-07-012025-09-30PAR2025-09-30PAR2025-03-31PAR2025-04-012025-09-30PAR2025-07-012025-09-30in-capmkt:OtherExpenses1MemberPAR2025-04-012025-09-30in-capmkt:OtherExpenses1MemberPAR2025-07-012025-09-30RelatedPartyTransactionDomain1PAR2025-06-30RelatedPartyTransactionDomain1PAR2025-09-30RelatedPartyTransactionDomain1PAR2025-07-012025-09-30RelatedPartyTransactionDomain2PAR2025-06-30RelatedPartyTransactionDomain2PAR2025-09-30RelatedPartyTransactionDomain2PAR2025-07-012025-09-30RelatedPartyTransactionDomain3PAR2025-06-30RelatedPartyTransactionDomain3PAR2025-09-30RelatedPartyTransactionDomain3PAR2025-07-012025-09-30RelatedPartyTransactionDomain4PAR2025-06-30RelatedPartyTransactionDomain4PAR2025-09-30RelatedPartyTransactionDomain4PAR2025-07-012025-09-30RelatedPartyTransactionDomain5PAR2025-06-30RelatedPartyTransactionDomain5PAR2025-09-30RelatedPartyTransactionDomain5PAR2025-07-012025-09-30RelatedPartyTransactionDomain6PAR2025-06-30RelatedPartyTransactionDomain6PAR2025-09-30RelatedPartyTransactionDomain6PAR2025-07-012025-09-30RelatedPartyTransactionDomain7PAR2025-06-30RelatedPartyTransactionDomain7PAR2025-09-30RelatedPartyTransactionDomain7PAR2025-07-012025-09-30RelatedPartyTransactionDomain8PAR2025-06-30RelatedPartyTransactionDomain8PAR2025-09-30RelatedPartyTransactionDomain8PAR2025-07-012025-09-30RelatedPartyTransactionDomain9PAR2025-06-30RelatedPartyTransactionDomain9PAR2025-09-30RelatedPartyTransactionDomain9PAR2025-07-012025-09-30RelatedPartyTransactionDomain10PAR2025-06-30RelatedPartyTransactionDomain10PAR2025-09-30RelatedPartyTransactionDomain10PAR2025-07-012025-09-30RelatedPartyTransactionDomain11PAR2025-06-30RelatedPartyTransactionDomain11PAR2025-09-30RelatedPartyTransactionDomain11PAR2025-07-012025-09-30RelatedPartyTransactionDomain12PAR2025-06-30RelatedPartyTransactionDomain12PAR2025-09-30RelatedPartyTransactionDomain12PAR2025-07-012025-09-30RelatedPartyTransactionDomain13PAR2025-06-30RelatedPartyTransactionDomain13PAR2025-09-30RelatedPartyTransactionDomain13PAR2025-07-012025-09-30RelatedPartyTransactionDomain14PAR2025-06-30RelatedPartyTransactionDomain14PAR2025-09-30RelatedPartyTransactionDomain14PAR2025-07-012025-09-30RelatedPartyTransactionDomain15PAR2025-06-30RelatedPartyTransactionDomain15PAR2025-09-30RelatedPartyTransactionDomain15iso4217:INRiso4217:INRxbrli:shares000000PARNOTLISTEDINE04LG01015PAR DRUGS AND CHEMICALS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-132025-11-03INRLakhsQuarterlySecond quarterSingle segmentThe Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108.2025-11-1315:30:002025-11-1316:28:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-05-08https://pardrugs.com/policies-par-drugs-and-chemicals.phpfalsefalseAs there is no any outstanding default on loans and debt securities as on 30.09.2025 hence not applicale to the company.2025-07-012025-09-30UnauditedStandalone2865890004801000291390000105423000018130001354900054900094110001051430002358880005550200005550200014206000014206000041296000000041296000041296000123046000103.363.36003.363.361. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time. <BR> <BR> 2. The above quarterly and half year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November, 2025. <BR> <BR> 3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & half yearly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. <BR> <BR> 4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS. <BR> <BR> 5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures. <BR> <BR> 6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108. <BR> <BR> 7. The Company does not have any subsidiary, associates or joint venture as on 30th September, 2025; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company. <BR> <BR> 8. The above unaudited financial results of the Company are available on the Company’s website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company’s shares are listed. <BR> <BR> 9. The Status of investors complaints are as follows: <BR> I. Pending at the beginning of the quarter - 0 <BR> II. Received during the quarter - 0 <BR> III. Disposed-off during the quarter - 0 <BR> IV. Remaining unresolved at the end of the quarter - 0 <BR> 2025-04-012025-09-30UnauditedStandalone54705300023169000570222000217055000035350002774500071200018445000202450000469942000100280000010028000025703000025703000074577000000074577000074577000123046000106.066.06006.066.06Other expenses105143000Other expenses202450000377048000689000000000267224000000267224000059440006509050005279000001762800003385560000878000051571400054262000156400062433000000127523500012304600094128000010643260001064326000000000035800000003580000004710000855140009022400009022400010719000741660000017510900000210909000127523500008269000-91390000-239000-503000000-186900000-25600001844500002666000-2666000000053880000000-600000-750700092773000000118260000809470000000000018300072110000165230000000000000000000538800000-18163000000000000000000062784000062784000275772000338556000Par Drugs And Chemicals Limited******Falgunbhai V Savani******Managing DirectorRemunerationNil2575000297000299000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India. Par Drugs And Chemicals Limited******Falgunbhai V Savani******Managing DirectorAny other transactionDirector Sitting FeesNil1000000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Jigneshbhai V Savani******Director & CEORemunerationNil2575000315000314000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India. Par Drugs And Chemicals Limited******Jigneshbhai V Savani******Director & CEOAny other transactionDirector Sitting FeesNil500000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Ghanshyambhai B Savani******Prodcution Head (Promoter Group)RemunerationNil25750000429000Par Drugs And Chemicals Limited******Savani Prathambhai Ghanshyambhai******Relative of Promoter Group (Son of Ghanshyambhai B. Savani)RemunerationNil2140002500027000Par Drugs And Chemicals Limited******Sanket Bhupendrabhai Trivedi******Company SecretaryRemunerationNil4370005200057000Par Drugs And Chemicals Limited******Chintan Pratapbhai Chauhan******Chief Financial OfficerRemunerationNil4030004800053000Par Drugs And Chemicals Limited******Naynaben J Savani******Non-Executive DirectorAny other transactionDirector Sitting FeesNil050000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Kajal Chitanbhai Vaghani******Independent DirectorAny other transactionDirector Sitting FeesNil10000230000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Krishna Mitulbhai Shah******Independent DirectorAny other transactionDirector Sitting FeesNil10000270000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Pravin Manjibhai Bhayani******Independent DirectorAny other transactionDirector Sitting FeesNil1000000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******Pravin Manjibhai Bhayani******Independent DirectorRemunerationNil120000057000180000By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2024, the Board at its meeting held on 17/08/2024 considered and approved remuneration payable, which is subsequently approved by the shareholders for the period of one year w.e.f. 1st October, 2024 to 30th September, 2025 in the 25th Annual General Meeting held on Saturday, 21st Day of September, 2024 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, IndiaPar Drugs And Chemicals Limited******Bintal Bhaveshkumar Shah******Independent DirectorAny other transactionDirector Sitting FeesNil5000160000 By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.Par Drugs And Chemicals Limited******PHAL-JIG FINE CHEMICALS PRIVATE LIMITED******Enterprise in which significant influence is exercised by KMPAny other transactionPart Payment of Consideration for purchase of Business unit950000000Nil051000005100000By considering the suggestion and approval of Audit Committee and Board meeting held on 11/01/2025 considered and approved the transaction , which is subsequently approved by the shareholders in the Extra-Ordinary General Meeting (“EGM”) (Meeting No. 02/EGM/2024-25) of the Members of PAR DRUGS AND CHEMICALS LIMITED (“Company”) held on Wednesday, 12th Day of February, 2025 at 3:00 P.M. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”)10029000